Alkermes (Alkermes) Change In Receivables

: $-36 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Alkermes's change in receivables for the quarter that ended in Dec. 2023 was $7 Mil. It means Alkermes's Accounts Receivable declined by $7 Mil from Sep. 2023 to Dec. 2023 .

Alkermes's change in receivables for the fiscal year that ended in Dec. 2023 was $-36 Mil. It means Alkermes's Accounts Receivable increased by $36 Mil from Dec. 2022 to Dec. 2023 .

Alkermes's Accounts Receivable for the quarter that ended in Dec. 2023 was $230 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Alkermes's Days Sales Outstanding for the three months ended in Dec. 2023 was 55.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alkermes's liquidation value for the three months ended in Dec. 2023 was $105 Mil.

Alkermes Change In Receivables Historical Data

The historical data trend for Alkermes's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

29.98

-24.07

-31.97

29.68

-36.29

Alkermes Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-29.62	19.29	-56.87	-5.99	7.28

Alkermes Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36 Mil.

Alkermes (NAS:ALKS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alkermes's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	229.577	/	377.475	*	91
=	55.50

2. In Ben Graham's calculation of liquidation value, Alkermes's accounts receivable are only considered to be worth 75% of book value:

Alkermes's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	773.491	-	933.537	+	0.75 * 229.577	+	0.5 * 186.406
=	105

Alkermes Change In Receivables Related Terms

Thank you for viewing the detailed overview of Alkermes's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes (Alkermes) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Executives

Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols	officer: SVP, Chief Commercial Officer	852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr.	director	ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright	director	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine	officer: SVP, Corp Dev., Alkermes, Inc.	88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops	director, officer: Director and CEO, Alkermes plc	10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke	officer: President, Alkermes plc	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson	officer: EVP, Chief Operating Officer	852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson	officer: SVP, Med Dev/Med Affairs, CMO	852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown	officer: VP, Finance & CAO	14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon	director	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin	officer: SVP, CLO, Alkermes, Inc.	852 WINTER STREET, WALTHAM MA 02451